KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
about
Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic targetChildhood acute lymphoblastic leukemia: Integrating genomics into therapyThe role of the RAS pathway in iAMP21-ALL.Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes.High hyperdiploid childhood acute lymphoblastic leukemia: Chromosomal gains as the main driver event.Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence.Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group.Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia.Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.Genetics and epigenetics of pediatric leukemia in the era of precision medicine
P2860
Q28070887-7D8A9333-A43E-4E8D-8C87-7F0E4D3686ACQ28080463-4E9881D4-0629-4F65-9D29-86BCFA70F417Q37245131-7E780F4D-39FE-4371-AD21-3EC31D347EE6Q37262456-C567F793-0B69-419F-AA23-AA4490F50BE8Q37322911-FE11F658-C335-4CD9-A36E-888E19414D8BQ37322952-8F221E83-E365-4006-A0C1-D4DF86577D01Q37555816-C072EFAA-B43F-4DA0-BF66-CA37829F68A1Q37629537-13335E7B-519E-4A36-AC71-5DA98AED7911Q37687285-26FFFE73-E879-478D-8DEE-837B61D5B237Q38726062-62715516-AB74-4AA2-A068-F258657B54FBQ38800499-E9A1C3CF-75FD-4FCD-B3A8-6E0B0A78E5C4Q39041475-7C9738F6-D9E5-47E5-AA3B-BB7AD607A12EQ39883150-C46EEE50-E59B-45E0-89A8-11CE7C41593CQ40632435-1B3BDF3A-32B5-475A-AB92-53A99FE63EEAQ41000106-910DE559-83D5-43FA-ABAA-0B421147BEEDQ42350797-D5A67836-40DB-442C-A3B3-8A3FFF0DDB22Q45233800-1591A278-2725-4040-9113-F5E3FD3711C5Q46355299-7131D783-AC47-47D0-B563-81217CE92737Q47752623-1B1EA309-5AFE-40B5-BB3F-E852B03251FFQ47875530-6D6CED57-571C-4310-B38C-E99087AB227CQ48146880-16474AC4-8B58-401F-B0B9-B17E69313A0AQ48219436-9B8BAB68-7F2F-4023-877B-48B522A66702Q50001759-C9E679A7-4809-46DB-825F-614FE87C3D2DQ51839566-D3A308F8-7B7A-498B-BD19-5928767FECADQ57175475-76ED8D2B-AF4C-49D3-8AF2-B4E68365ED28
P2860
KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
KRAS and CREBBP mutations: a r ...... acute lymphoblastic leukemia.
@ast
KRAS and CREBBP mutations: a r ...... acute lymphoblastic leukemia.
@en
type
label
KRAS and CREBBP mutations: a r ...... acute lymphoblastic leukemia.
@ast
KRAS and CREBBP mutations: a r ...... acute lymphoblastic leukemia.
@en
altLabel
KRAS and CREBBP mutations: a r ...... d acute lymphoblastic leukemia
@en
prefLabel
KRAS and CREBBP mutations: a r ...... acute lymphoblastic leukemia.
@ast
KRAS and CREBBP mutations: a r ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P356
P1433
P1476
KRAS and CREBBP mutations: a r ...... acute lymphoblastic leukemia.
@en
P2093
A Attarbaschi
A Mecklenbräuker
A Schönegger
A von Stackelberg
D Kneidinger
F Locatelli
G Cazzaniga
P2860
P2888
P304
P356
10.1038/LEU.2015.107
P407
P577
2015-04-28T00:00:00Z